David Mares, MD
Pulmonary Disease · Anderson, INNPI 1396770335
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,195,843 of the $1,332,363 with a category attached, or 89.8%. AstraZeneca accounts for 70.7% of it on its own, with 41 other manufacturers making up the rest. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,753 payments — averaging $760.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$942K
- Grifols USA, LLC$150K
- Mylan Specialty L.p.$74K
- Boehringer Ingelheim$49K
- Regeneron Healthcare Solutions, Inc.$33K
- Viatris Specialty LLC$27K
- plus $59K from 36 others
What the payments were for
- Consulting fees$34,2393%
- Speaking & faculty fees$1,195,84390%
- Travel & lodging$61,0165%
- Food & beverage$40,9193%
- Education$3470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$384,780
- BREZTRI$260,738
- TEZSPIRE$213,121
- Prolastin-C Liquid$119,663
- Yupelri$98,978
- AIRSUPRA$53,066
- BREZTRI AEROSPHERE$26,579
- Prolastin-C$20,422
- DUPIXENT$19,964
- Ohtuvayre$10,670
- Xembify$10,305
- LONHALA MAGNAIR$6,912
- XOLAIR$1,455
- SYMBICORT$1,250
- Brinsupri$279
- CAMZYOS$144
- NUCALA$122
How this compares
$1,332,363 in reported general payments places this provider in the 95th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 51 | $602,736 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 347 | $282,769 |
| Fasenra PenBenralizumab | 36 | $202,632 |
| TezspireTezepelumab-Ekko | 44 | $184,656 |
| FasenraBenralizumab | 29 | $160,331 |
| Dupixent SyringeDupilumab | 29 | $116,620 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 140 | $107,714 |
| HyqviaIgg/Hyaluronidase,recombinant | 13 | $92,808 |
| NucalaMepolizumab | 25 | $91,111 |
| XolairOmalizumab | 28 | $82,574 |
| Spiriva RespimatTiotropium Bromide | 101 | $68,149 |
| EliquisApixaban | 78 | $53,812 |
| Breo ElliptaFluticasone/Vilanterol | 88 | $50,061 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 152 | $41,304 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 49 | $34,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $149,555 | $602,73651 claims |
| AstraZenecaTezspire, Fasenra, Breztri Aerosphere, Symbicort | $941,654 | $484,313299 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,694 | $446,307498 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $48,939 | $118,290169 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $252 | $92,80813 claims |
| PfizerEliquis, Nurtec Odt | $369 | $70,32992 claims |
| Johnson & JohnsonXarelto | $364 | $12,77011 claims |
| MerckDulera | $108 | $10,39522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Anderson
- Pablo MolinaAnderson$15K
- Naeem MalikAnderson$11K
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.